Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.28 Insider Own0.40% Shs Outstand143.62M Perf Week1.68%
Market Cap8.50B Forward P/E- EPS next Y-1.08 Insider Trans48.26% Shs Float143.20M Perf Month-19.70%
Income-176.40M PEG- EPS next Q-0.45 Inst Own99.90% Short Float4.66% Perf Quarter-19.22%
Sales548.50M P/S15.50 EPS this Y-34.70% Inst Trans-0.03% Short Ratio3.96 Perf Half Y-11.25%
Book/sh9.40 P/B6.30 EPS next Y40.30% ROA-10.00% Target Price83.63 Perf Year-8.97%
Cash/sh5.46 P/C10.83 EPS next 5Y25.00% ROE-13.80% 52W Range53.53 - 84.25 Perf YTD-15.86%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-29.74% Beta0.92
Dividend %- Quick Ratio5.30 Sales past 5Y13.10% Gross Margin82.60% 52W Low10.57% ATR3.15
Employees1341 Current Ratio6.20 Sales Q/Q11.40% Oper. Margin-27.50% RSI (14)32.79 Volatility4.15% 5.13%
OptionableYes Debt/Eq0.49 EPS Q/Q0.00% Profit Margin-32.10% Rel Volume1.21 Prev Close59.19
ShortableYes LT Debt/Eq0.49 EarningsMay 01 AMC Payout- Avg Volume1.69M Price59.19
Recom2.00 SMA20-6.83% SMA50-18.06% SMA200-14.18% Volume0 Change0.00%
19-Feb-14Reiterated Barclays Equal Weight $73 → $76
14-Jan-14Reiterated Deutsche Bank Buy $75 → $85
10-Jan-14Downgrade Barclays Overweight → Equal Weight $75 → $73
25-Oct-13Reiterated Barclays Overweight $70 → $75
18-Sep-13Downgrade Stifel Buy → Hold
26-Jul-13Reiterated Stifel Buy $67 → $70
03-Apr-13Reiterated Barclays Overweight $54 → $70
20-Mar-13Reiterated RBC Capital Mkts Outperform $58 → $64
20-Mar-13Reiterated Deutsche Bank Hold $45 → $59
22-Feb-13Reiterated RBC Capital Mkts Outperform $55 → $58
01-Feb-13Reiterated UBS Buy $53 → $67
22-Jan-13Upgrade Stifel Nicolaus Hold → Buy $67
06-Nov-12Reiterated Barclays Overweight $46 → $54
06-Nov-12Downgrade Brean Capital Buy → Hold
28-Sep-12Reiterated Summer Street Research Buy $45 → $52
27-Aug-12Downgrade Deutsche Bank Buy → Hold $40 → $45
24-Aug-12Initiated Barclays Overweight $46
12-Apr-12Initiated UBS Buy $43
26-Mar-12Initiated Canaccord Genuity Buy $43
19-Mar-12Upgrade Brean Murray Hold → Buy $41
23-Apr-14 08:48AM  Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases at Seeking Alpha
17-Apr-14 06:32PM  How Are Orphan Drugmakers Faring in the Great Biotech Downturn? at Motley Fool
16-Apr-14 09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks +5.43%
08:00AM  BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET GlobeNewswire
14-Apr-14 06:15PM  [video] The IPO plague at CNBC
08:22AM  BioMarin says FDA extends Kuvan market exclusivity by six months theflyonthewall.com
08:00AM  FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets GlobeNewswire
11-Apr-14 06:25AM  Cramer's Lightning Round - The IPOs Are A Curse On The Market (4/10/14) at Seeking Alpha -6.59%
06:00AM  'Mad Money' Lightning Round: I Don't See a BioMarin Rally at TheStreet
10-Apr-14 06:44PM  Lightning Round: BioMarin, Carriage Services & More at CNBC -6.85%
03:03PM  'Very Volatile' Biotech, in Chart Form at The Wall Street Journal
07-Apr-14 09:03AM  The AACR Annual Meeting May Move These 2 Stocks at Motley Fool
04-Apr-14 08:31AM  Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs at Seeking Alpha
02-Apr-14 11:55AM  Uniqure rises after Baxter acquires Chatham Therapeutics at theflyonthewall.com
28-Mar-14 01:03PM  3 Stocks Pushing The Health Care Sector Downward at TheStreet
27-Mar-14 11:02AM  Biomarin Pharmaceutical (BMRN) Showing Signs Of Being A Roof Leaker at TheStreet
26-Mar-14 06:00AM  Once Seen As Too Scary, Editing People's Genes With Viruses Makes A $618 Million Comeback at Forbes
06:00AM  Gene Therapy's Big Comeback at Forbes
25-Mar-14 12:46PM  Biotech comeback stalls as Wall Street starts to worry at MarketWatch
12:19PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
11:01AM  Jim Cramer: Wait for the All-Clear at TheStreet
07:20AM  Wait for the All-Clear TheStreet
06:53AM  BioMarin pullback a buying opportunity, says RW Baird theflyonthewall.com
21-Mar-14 08:00AM  BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors GlobeNewswire -5.91%
20-Mar-14 08:20AM  Narrower-than-Expected Loss at Catalyst Pharma Zacks
19-Mar-14 06:32PM  Shorts Piling on to Myriad Genetics: Time to Panic? at Motley Fool
13-Mar-14 05:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi EDGAR Online
11-Mar-14 09:12PM  Company Makes Drug Available To Ailing Boy Following Public Outcry at Forbes
06-Mar-14 05:13PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S EDGAR Online
05-Mar-14 08:00AM  BioMarin Announces Pricing of Public Offering of Common Stock GlobeNewswire
04-Mar-14 04:23PM  BioMarin files to sell 1.5M shares of common stock at theflyonthewall.com
04:23PM  BioMarin files to sell 1.5M shares of common stock
04:21PM  BioMarin Announces Public Offering of Common Stock GlobeNewswire
01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
08:00AM  BioMarin to Present at the Barclays Global Healthcare Conference in Miami GlobeNewswire
03-Mar-14 03:11PM  BioMarin Pharmaceutical, Inc.: Is This Orphan Drug Specialist Overvalued? at Motley Fool
28-Feb-14 05:55PM  With economy on ice, bulls push for more new highs at CNBC
05:55PM  Ukraine looms as markets push toward new highs Optionetics
05:55PM  Ukraine looms as markets push toward new highs at CNBC
05:55PM  Ukraine looms as markets push toward new highs
27-Feb-14 01:00PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
08:50AM  Loss at BioMarin Narrower Than Expected Zacks
26-Feb-14 05:15PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report EDGAR Online
04:05PM  BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results GlobeNewswire
25-Feb-14 09:56AM  Is NPS Pharmaceuticals The Next Alexion? at Seeking Alpha
08:00AM  BioMarin to Present at the Cowen Healthcare Conference in Boston GlobeNewswire
24-Feb-14 02:01PM  Can Alexion Pharmaceuticals Remain a Top Orphan Drugmaker in the Years Ahead? at Motley Fool
23-Feb-14 05:11PM  BioMarin Pharmaceutical Inc: The Future Looks Bright at Motley Fool
21-Feb-14 02:05PM  BioMarin Rises on Favorable CHMP Opinion Zacks
20-Feb-14 11:21AM  BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome GlobeNewswire
19-Feb-14 08:27AM  Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug Zacks
08:00AM  BioMarin to Present at Two Upcoming Investor Conferences in New York GlobeNewswire
18-Feb-14 10:35PM  Biotech Continues to Lead Market: Innovation and M&A at TheStreet
02:27PM  Rare Early Success Of Ultragenyx Pharmaceuticals Could Continue With Expiration Of Quiet Period at Seeking Alpha
11:10AM  FDA Clears BioMarin's Vimizim Zacks
09:30AM  BioMarin Prices New Drug For Ultra-Rare Disease at $380K Per Year at TheStreet
08:28AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:08AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
17-Feb-14 03:00PM  BioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results GlobeNewswire
14-Feb-14 06:31PM  Myriad Is Angling for Gene Dominance at Motley Fool
04:30PM  BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome GlobeNewswire
13-Feb-14 02:31PM  What You Need to Know About BioMarin's Vimizim Ahead of the FDA Decision at Motley Fool
08:00AM  BioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network's 10th Annual WORLDSymposium(TM) GlobeNewswire
11-Feb-14 08:00AM  BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB) GlobeNewswire
10-Feb-14 11:03AM  Will Illumina's Big Move Continue in 2014? at Motley Fool
05-Feb-14 08:00AM  BioMarin to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast on Monday, March 3 at 8:00 a.m. ET GlobeNewswire
04-Feb-14 09:55AM  UniQure IPO Could Heal What Ails Investors In 2014 at Seeking Alpha
29-Jan-14 12:50PM  Catalent leads parade of drugmakers headed to market at TheStreet
12:50PM  Catalent leads parade of drugmakers headed to market
28-Jan-14 06:33PM  The 3 Most Ridiculous Biotech Buyout Rumors Over the Past Year at Motley Fool
06:33PM  The 3 Most Ridiculous Biotech Buyout Rumors Over the Past Year
27-Jan-14 08:14AM  BioMarin price target raised to $84 from $78 at Leerink at theflyonthewall.com
08:14AM  BioMarin price target raised to $84 from $78 at Leerink
23-Jan-14 11:10AM  BioMarin's Pipeline Encourages Zacks
11:10AM  BioMarin's Pipeline Encourages
22-Jan-14 09:05AM  Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside
06:36AM  Cramer's Lightning Round - Stay Long Kinder Morgan Partners (1/21/14) at Seeking Alpha
06:36AM  Cramer's Lightning Round - Stay Long Kinder Morgan Partners (1/21/14)
06:00AM  'Mad Money' Lightning Round: Stay Long on Kinder Morgan at TheStreet
06:00AM  'Mad Money' Lightning Round: Stay Long on Kinder Morgan
21-Jan-14 06:40PM  Lightning Round: BP, Kinder Morgan & More at CNBC
06:40PM  Lightning Round: BP, Kinder Morgan & More
07:35AM  BioMarin Announces Agreement With Repligen for Pre-clinical Compounds GlobeNewswire
07:35AM  BioMarin Announces Agreement With Repligen for Pre-clinical Compounds
17-Jan-14 11:36AM  Drugmakers see innovation justifying further price rises Reuters
15-Jan-14 05:20PM  Pipeline Progress at BioMarin Zacks
05:20PM  Pipeline Progress at BioMarin
14-Jan-14 10:44AM  Jim Cramer's 6 Stocks in 60 Seconds: GIS CLF BMRN YUM CELG SSYS at TheStreet
10:44AM  Jim Cramer's 6 Stocks in 60 Seconds: GIS CLF BMRN YUM CELG SSYS
08:15AM  UBS Has Nine Biotech Buyout and Merger Candidates
08:00AM  BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia GlobeNewswire
08:00AM  BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia
13-Jan-14 08:05AM  American College of Medical Genetics and Genomics Practice Guidelines Support Lifelong Therapy to Manage Phenylketonuria (PKU) GlobeNewswire
08:05AM  American College of Medical Genetics and Genomics Practice Guidelines Support Lifelong Therapy to Manage Phenylketonuria (PKU)
08:00AM  BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A GlobeNewswire
08:00AM  BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
10-Jan-14 02:35PM  What's Next for Biotech? at Barrons.com
02:35PM  What's Next for Biotech?
12:26PM  Biomarin Pharm downgraded by Barclays Briefing.com
12:26PM  Biomarin Pharm downgraded by Barclays
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Option Exercise27.2417,370473,16542,750Mar 10 06:16 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Sale78.6317,3701,365,83125,380Mar 10 06:16 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Option Exercise39.068,000312,48072,273Mar 05 04:40 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Sale80.328,000642,53064,273Mar 05 04:40 PM
Davis George EricSVP, General CounselFeb 20Option Exercise21.5120,000430,20080,656Feb 24 06:51 PM
Davis George EricSVP, General CounselFeb 20Sale80.0020,0001,600,00060,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 20Sale80.008,000640,00046,740Feb 24 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 06Option Exercise12.994,00051,96054,740Feb 07 04:53 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Option Exercise21.5110,000215,10052,350Feb 04 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Sale67.7010,000676,96642,350Feb 04 06:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise12.995,00064,95055,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale70.005,000350,00050,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise12.9910,000129,90060,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale67.4110,000674,09650,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Option Exercise12.995,00064,95055,740Jan 06 04:08 PM
FUCHS HENRY JEVP, Chief Medical OfficerJan 02Sale68.9791663,17242,350Jan 06 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Sale68.905,000344,48350,740Jan 06 04:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale68.7110,000687,14350,740Dec 27 12:07 PM
GREY MICHAEL GDirectorDec 11Option Exercise21.7130,000651,30053,050Dec 13 06:07 PM
GREY MICHAEL GDirectorDec 11Sale69.6630,0002,089,68023,050Dec 13 06:07 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Option Exercise19.4413,026253,18327,906Dec 11 07:15 PM
LEWIS ALANDirectorDec 09Option Exercise30.5222,500686,77541,800Dec 11 08:21 PM
LEWIS ALANDirectorDec 09Sale69.9122,5001,572,98219,300Dec 11 08:21 PM
LAWLIS V BRYANDirectorDec 09Sale69.762,900202,30111,400Dec 11 07:17 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Sale69.5513,026906,01014,880Dec 11 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 05Sale69.705,000348,48550,740Dec 09 07:42 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Option Exercise39.069,000351,54046,950Dec 04 04:15 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Sale70.149,000631,27337,950Dec 04 04:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 14Option Exercise12.995,00064,95050,740Nov 18 05:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Option Exercise12.995,00064,95050,740Nov 07 05:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Sale62.365,000311,77945,740Nov 07 05:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 01Sale63.16996,25314,880Nov 05 07:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Option Exercise12.9910,000129,90055,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Sale62.7210,000627,15545,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 16Option Exercise12.992,00025,98047,740Oct 18 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 16Sale67.732,000135,45045,740Oct 18 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 10Sale66.763,000200,29145,740Oct 15 08:17 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 19Option Exercise11.0510,000110,50053,266Sep 23 04:37 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 19Sale80.1910,000801,90043,266Sep 23 04:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Option Exercise12.992,00025,98050,740Sep 18 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Sale73.082,000146,16348,740Sep 18 02:35 PM
BAFFI ROBERTEVP, Technical OperationsSep 09Option Exercise21.5120,000430,20082,262Sep 11 09:58 AM
BAFFI ROBERTEVP, Technical OperationsSep 09Sale73.0020,0001,460,00062,262Sep 11 09:58 AM
FUCHS HENRY JEVP, Chief Medical OfficerSep 05Option Exercise11.0510,000110,50053,266Sep 09 05:13 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 05Sale70.0010,000700,00043,266Sep 09 05:13 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 04Option Exercise39.069,000351,54046,950Sep 05 06:51 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 04Sale69.009,000621,00037,950Sep 05 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 15Option Exercise12.991,00012,99049,740Aug 19 05:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 15Sale64.361,00064,36448,740Aug 19 05:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 15Option Exercise12.991,00012,99049,740Jul 17 04:36 PM
FUCHS HENRY JEVP, Chief Medical OfficerJul 01Option Exercise11.0510,000110,50053,266Jul 02 05:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJul 01Sale59.784,066243,06337,950Jul 02 05:29 PM
FUCHS HENRY JEVP, Chief Medical OfficerJul 01Sale60.0010,000600,00043,266Jul 02 05:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 12Option Exercise12.995,00064,95048,740Jun 14 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Option Exercise12.9910,000129,90053,740Jun 07 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Option Exercise12.9910,000129,90053,740Jun 04 05:47 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 03Sale58.3449328,76314,880Jun 04 06:54 PM
FUCHS HENRY JEVP, Chief Medical OfficerJun 03Sale58.321,09864,03643,266Jun 05 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Option Exercise12.993,00038,97043,740Jun 04 05:47 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 23Sale67.168,710584,98144,364May 24 03:15 PM
Wood MarkVP, Human ResourcesMay 22Option Exercise23.333,10372,40523,380May 23 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 22Option Exercise11.0510,000110,50064,973May 24 03:15 PM
Wood MarkVP, Human ResourcesMay 22Sale67.123,103208,28320,277May 23 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 22Sale65.6611,899781,24053,074May 24 03:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Option Exercise12.992,00025,98032,609May 23 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale64.142,000128,27930,609May 23 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise64.015,000320,05030,609May 17 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 16Option Exercise49.897,000349,24825,609May 17 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 16Sale64.652,000129,30720,609May 17 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 15Option Exercise12.9910,000129,90030,609May 17 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 15Sale68.5510,000685,47720,609May 17 07:15 PM
Davis George EricSVP, General CounselMay 14Option Exercise21.5120,000430,20061,708May 15 01:57 PM
Mueller BrianVP, Corporate ControllerMay 14Option Exercise21.513,50075,28510,160May 15 01:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Option Exercise12.9915,000194,85035,609May 15 02:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Option Exercise12.9925,000324,75045,609May 15 01:52 PM
BAFFI ROBERTEVP, Technical OperationsMay 14Option Exercise21.5120,000430,20070,262May 15 01:55 PM
BAFFI ROBERTEVP, Technical OperationsMay 14Sale70.0020,0001,400,00050,262May 15 01:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Sale70.9425,0001,773,55120,609May 15 01:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Sale70.1715,0001,052,49220,609May 15 02:45 PM
Mueller BrianVP, Corporate ControllerMay 14Sale70.354,947348,0456,660May 15 01:59 PM
Davis George EricSVP, General CounselMay 14Sale70.3420,0001,406,80041,708May 15 01:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 13Option Exercise12.998,000103,92028,609May 14 02:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 13Sale69.118,000552,89620,609May 14 02:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 13Sale68.537,000479,72088,101May 14 02:21 PM
Davis George EricSVP, General CounselMay 13Sale69.292,590179,45241,708May 14 02:00 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale69.261,24886,4317,270May 14 08:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale67.4880053,985111,038May 14 02:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale66.0081153,5289,270May 10 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale65.881,00065,879118,317May 09 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Option Exercise12.993,00038,97016,545May 09 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Sale65.873,000197,61313,545May 09 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 03Option Exercise12.998,000103,92018,545May 07 04:10 PM
Davis George EricSVP, General CounselMay 03Option Exercise16.315,85495,45952,912May 07 07:17 PM
BAFFI ROBERTEVP, Technical OperationsMay 03Option Exercise14.3920,000287,80073,155May 07 07:18 PM
Mueller BrianVP, Corporate ControllerMay 03Option Exercise21.517,500161,32516,903May 06 08:05 PM
Mueller BrianVP, Corporate ControllerMay 03Sale67.117,500503,2959,403May 06 08:05 PM
BAFFI ROBERTEVP, Technical OperationsMay 03Sale67.0020,0001,340,00053,155May 07 07:18 PM
Davis George EricSVP, General CounselMay 03Sale67.195,854393,32747,058May 07 07:17 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 03Sale67.248,000537,95013,545May 07 04:10 PM